Therefore, it is mandatory today, according to the recent international guidelines, to systematically obtain, at diagnosis, the status of EGFR, ALK, ROS1, BRAF, NTRK, RET, and MET, for late-stage NS-NSCLC treatment [5,7]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.